Short answer
Immunome Inc. (IMNM) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$54M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$54M
- −29.3% YoY
- EPS (diluted)
- −$0.48
- +7.7% YoY
Source: XBRL data from the Immunome Inc. (IMNM) Q1 2026 10-Q on SEC EDGAR. USD.
Immunome Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Regulatory approval risk: NDA submitted for varegacestat, but Immunome has never obtained FDA marketing approval or submitted a BLA
- Financial risk: Accumulated deficit $782.0 million and net loss $53.8 million for the three months ended March 31, 2026
- Liquidity risk: Existing cash and cash equivalents expected to fund planned operations for at least 12 months from filing
- Clinical-development risk: Three early clinical-stage assets currently or expected soon in Phase 1 trials
- Market risk: Global credit markets face volatility from inflation, tariffs, geopolitical conflicts, and reduced liquidity availability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunome Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.